fashion -WSS

fashion

author：explore 2025-09-05 11:32:45 - browse：6

Scientists Christina Frey and Paul Negulescu work in a lab at Vertex Pharmaceuticals. -- biotech coverage from STAT — Scientists Christina Frey and Paul Negulescu work in a lab at Vertex Pharmaceuticals in San Diego. Sandy Huffaker for STAT

A pain relief drug developed by Vertex Pharmaceuticals succeeded in late-stage clinical trials, the company announced Tuesday, bringing the biopharma giant a step closer to launching what observers believe could be a potential blockbuster and upending decades of pharma failure in a complicated field.

In a pair of randomized, placebo-controlled Phase 3 trials for patients with pain after a tummy tuck or bunion surgery, the drug showed statistically significant pain reduction compared to placebo, meeting the primary endpoints for these studies and the expectations of market analysts. But the experimental therapy didn’t relieve pain better than a combination of acetaminophen and the opioid hydrocodone, a key secondary endpoint observers had been waiting on. And in the bunionectomy trial, the opioid comparator outperformed VX-548 at soothing pain.

The drug, a small molecule known as VX-548, blocks pain-sensing neurons from signaling the pain without the addictive potential of opioids. It was generally safe, with fewer patients on VX-548 reporting adverse events than those taking the placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： ASCO eve: Let’s set the table for this year's meeting

hotspot

WSS

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Eyeing GLP

FDA poised to publish guidelines for clinical trial diversity

For longer

Fentanyl is making it harder to start addiction treatment

UnitedHealth argues against case alleging wrongful AI care denials

explore

fashion

focus

Medicare proposal to cover medical devices draws a mixed reaction

Biogen joins immunology wave with $1.15 billion acquisition of HI

Virginia high school admissions case could be legal follow

Cue Health, Covid

Hepatitis C has a cure — but many Americans still lack access to it

Reports of telehealth's death have been greatly exaggerated

Heart attack and stroke risk calculators need revising

Sage considers ways to reduce costs following FDA rejection

ChatGPT in medicine: STAT answers readers' burning questions

Cue Health, Covid

hotspot

Citing H5N1 threat, CDC urges peak flu monitoring this summer

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Restaurant meals are packed with calories, and we still keep eating them

At flashy new research hub, AstraZeneca lays out ambitious growth goals

Addressing health care workers' trauma can help fight burnout

Listen: A conversation with researcher Kevin Esvelt on biosecurity

leisure time

hotspot

knowledge

entertainment